Brief: Mundipharma International, Mundipharma Medical Company, Acrotech Biopharma Enter Agreement To Transfer License Of FOLOTYN In China To CASI Pharmaceuticals
01/08/2023 12:18
Aug 1 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED, MUNDIPHARMA
MEDICAL COMPANY, AND ACROTECH BIOPHARMA INC. ENTER AGREEMENT TO
TRANSFER LICENSE OF FOLOTYN® (PRALATREXATE) IN CHINA TO CASI
PHARMACEUTICALS
* CASI PHARMACEUTICALS - UNDER TERMS OF DEAL, CASI WILL
ASSUME
MICL'S RIGHTS AND OBLIGATIONS WITH RESPECT TO COMMERCIALIZATION
OF FOLOTYN IN CHINA
Source text for Eikon: ID:nPn4c8fHha
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary